Kangyuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as Kangyuan Pharmaceutical Group) was formerly Shenzhen Taitai Health Food Co., Ltd. Founded by Chairman Zhu Baoguo in 1992, it established itself as the leading position in the health care product industry with a dose of "Taitai Oral Liquid". In 1995, it transformed into the pharmaceutical industry and was renamed Shenzhen Taitai Pharmaceutical Co., Ltd.; in 1997, it acquired Shenzhen Haibin Pharmaceutical Co., Ltd. and completed the successful transformation from a health care product enterprise to a pharmaceutical enterprise; in 1999, the shareholding transformation was completed and changed to Shenzhen Taitai Pharmaceutical Co., Ltd.; in 2001, Taitai Pharmaceutical was listed on the Shanghai Stock Exchange, successfully listed, issuing 70 million shares, raising 1.7 billion yuan, making it the private enterprise with the most funds raised on the A-share market at that time. Afterwards, Kangyuan Pharmaceutical Group successively acquired high-quality pharmaceutical companies such as Healthy Pharmaceutical (China) Co., Ltd. and Lizhu Pharmaceutical Group Co., Ltd.; in 2003, it was renamed Kangyuan Pharmaceutical Group Co., Ltd. Relying on years of focus on the pharmaceutical field, Kangyuan Pharmaceutical Group has developed from a well-known health care product company to a private pharmaceutical group with strong comprehensive strength in China.

Currently, there are more than 30 major holding subsidiaries under Kangyuan Pharmaceutical Group, with more than 500 drug varieties and more than 8,000 employees. The business scope covers health products, raw materials (including intermediates) and preparations, prescription and over-the-counter drugs, Chinese patent medicines and chemical preparations, testing reagents and other fields, and has begun to form an upstream and downstream industrial chain. Health Products owns well-known brands such as Taitai, Jingxin, and Yingpai; the raw materials (intermediates) include antibiotic series and their intermediates 7ACA (enzyme method), 4AA, F9, etc.; prescription drugs include gastrointestinal drugs, cardiovascular and cerebrovascular drugs, anti-infective drugs, anti-tumor drugs, neurocerebrovascular drugs, urinary system drugs, etc.; over-the-counter drugs include gastrointestinal drugs "Lizhu Dele" and "Lizhu Chanle", oral ulcer drugs "Yiketip", cold drugs "antiviral oral granules", skin external drugs "Xinfu Mi Ling Ointment", compound dexamethasone acetate cream, etc. In 2009, the total amount of drug purchases in hospitals in the country was ranked 5th among domestic companies and 12th among foreign companies (IMS data shows). The products of Kangyuan Pharmaceutical Group are also exported to the United States, Australia, Singapore, Malaysia, Hong Kong, Macao and Taiwan.

Shenzhen Haibin Pharmaceutical Co., Ltd., a subsidiary of Kangyuan Pharmaceutical Group, mainly produces and sells antibiotics, and regards the third-generation antibiotic carbapenems as its main development direction. It is now the world's largest carbapenem antibiotic production base and a high-tech enterprise in Shenzhen. Following the sterile meropenem (raw substances) of Haibin Pharmaceutical passed the EU GMP certification in 2011 and the sterile meropenem (injection powder) passed the EU GMP certification in 2012, in early 2014, Haibin Pharmaceutical obtained the EU CEP certificate. So far, Haibin Pharmaceutical has become the first domestic unit to pass the European CEP certification, and is also a domestic production unit that has the three certificates of sterile meropenem, sterile preparations (injection powder) certified by the EU EU-GMP, and sterile raw materials that have three certificates in one.

In 2002, Kangyuan Pharmaceutical Group acquired Lizhu Pharmaceutical Group Co., Ltd. and became the largest shareholder of Lizhu Pharmaceutical Group. In 2009, Lizhu Pharmaceutical Group completed its first B-share repurchase in the country, and its shares in Kangyuan Pharmaceutical Group rose to 45.31% again. In 1993, Lizhu Pharmaceutical Group successfully issued A and B shares on the Shenzhen Stock Exchange, making it the first listed pharmaceutical company in China to issue A and B shares at the same time. Lizhu Pharmaceutical Group's products include more than 400 varieties, including chemical raw materials, chemical preparations, Chinese patent medicines, etc., with rich product lines and wide brand awareness. Among the 307 varieties newly issued by the state in July 2009, more than 90 varieties and more than 190 product specifications.

In 2007, Jiaozuo Kangyuan Bioproducts Co., Ltd., a subsidiary of Kangyuan Pharmaceutical Group, was the first environmentally friendly "enzyme" method in the country to industrially produce 7-aminocephalosporin-the key intermediate of cephalosporins, 7-aminocephalosporin (referred to as 7-ACA), leading the industry's production process from chemical method to environmentally friendly enzyme method, and has now become the industry leader.

Xinxiang Haibin Pharmaceutical Co., Ltd., a subsidiary of Jianyuan Pharmaceutical Group, produces Meropenem intermediates 4AA, F9, imipenem cisstatin, etc. It is now a key enterprise in Xinxiang City and is the main supplier of Meropenem intermediates F9 and 4AA of Shenzhen Haibin Pharmaceutical Co., Ltd.